All In Biotech

Drug Trial Radar · NCT05813288

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 654 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

654

Actual

Start

Mar 27, 2023

Primary completion

Dec 8, 2025

Study completion Dec 8, 2025

Sponsor

Lead sponsor
Areteia TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.

Conditions

  • Eosinophilic Asthma
  • Asthma; Eosinophilic
  • Asthma

Interventions

  • Dexpramipexole DihydrochlorideDrug

    Oral administration of dexpramipexole tablet

  • PlaceboDrug

    Oral administration of placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of severe asthma exacerbations over 52 weeks.Time frame: Day 1 (baseline, pre-dose) through Week 52

Locations

282 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site 30001-287

    Mobile, Alabama

  • Research Site 30001-487

    Chandler, Arizona

  • Research Site 30001-462

    Peoria, Arizona

  • Research Site 30001-322

    Surprise, Arizona

  • Research Site 30001-458

    Tucson, Arizona

  • Research Site 30001-010

    Little Rock, Arkansas

  • Research Site 30001-502

    Canoga Park, California

  • Research Site 30001-485

    Inglewood, California

  • Research Site 30001-362

    Laguna Niguel, California

  • Research Site 30001-497

    Los Angeles, California

  • Research Site 30001-500

    Northridge, California

  • Research Site 30001-489

    Pasadena, California

  • Research Site 30001-501

    San Diego, California

  • Research Site 30001-434

    San Diego, California

  • Research Site 30001-484

    Santa Monica, California

  • Research Site 30001-304

    Valencia, California

  • Research Site 30001-305

    Valencia, California

  • Research Site 30001-291

    Jacksonville, Florida

  • Research Site 30001-318

    Maitland, Florida

  • Research Site 30001-311

    Miami, Florida

  • Research Site 30001-288

    Miami, Florida

  • Research Site 30001-310

    Miami, Florida

  • Research Site 30001-329

    Miami, Florida

  • Research Site 30001-082

    Miami, Florida

  • Research Site 30001-301

    Naples, Florida

  • Research Site 30001-348

    Ocala, Florida

  • Research Site 30001-331

    Orlando, Florida

  • Research Site 30001-293

    Orlando, Florida

  • Research Site 30001-312

    Pembroke Pines, Florida

  • Research Site 30001-429

    Plantation, Florida

  • Research Site 30001-319

    Viera, Florida

  • Research Site 30001-452

    Dunwoody, Georgia

  • Research Site 30001-483

    East Point, Georgia

  • Research Site 30001-366

    Lilburn, Georgia

  • Research Site 30001-328

    Maywood, Illinois

  • Research Site 30001-535

    Westchester, Illinois

  • Research Site 30001-347

    Louisville, Kentucky

  • Research Site 30001-437

    Alexandria, Louisiana

  • Research Site 30001-286

    Lafayette, Louisiana

  • Research Site 30001-313

    Marrero, Louisiana

Showing 40 of 282 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.